G1 Therapeutics, Inc.
GTHXDelisted Sep 18, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001560241
G1 Therapeutics, Inc. was delisted on Sep 18, 2024; its insiders filed their last Form 4 on Sep 18, 2024; 88 institutions reported holding it in 13F filings for Q2 2024, worth $45.5M in total; no superinvestor held it.
13F holders, Q4 2022
Institutional positions in G1 Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +12 vs. Q3 2022
- Shares held
- 23.0M
- −27.3K (−0.1%) vs. Q3 2022
- Total value
- $125.1M
- −$162.4M (−56.5%) vs. Q3 2022
- New holders
- 36
- 32 more added
- Sold out
- 24
- 30 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GTHX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 88 | $45.5M |
| Q1 2024 | 86 | $61.6M |
| Q4 2023 | 87 | $38.5M |
| Q3 2023 | 72 | $15.8M |
| Q2 2023 | 80 | $38.6M |
| Q1 2023 | 97 | $51.5M |
| Q4 2022 | 116 | $125.1M |
| Q3 2022 | 104 | $287.5M |
| Q2 2022 | 98 | $98.2M |
| Q1 2022 | 115 | $183.8M |
| Q4 2021 | 108 | $270.6M |
| Q3 2021 | 115 | $357.8M |
| Q2 2021 | 114 | $541.8M |
| Q1 2021 | 123 | $582.2M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding G1 Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 370,673 | $2.01M | 0.00% | +32,379+9.6% | Added |
| Susquehanna International Group, LLP | 377,792 | $2.05M | 0.00% | +203,830+117.2% | Added |
| Qube Research & Technologies Ltd | 400,021 | $2.17M | 0.01% | +309,012+339.5% | Added |
| Two Sigma Investments, LP | 403,303 | $2.19M | 0.01% | +141,121+53.8% | Added |
| Tekla Capital Management LLC | 423,869 | $2.30M | 0.09% | 00.0% | Unchanged |
| D. E. Shaw & Co., Inc. | 444,707 | $2.41M | 0.00% | +349,733+368.2% | Added |
| Raymond James & Associates | 498,903 | $2.71M | 0.00% | +19,268+4.0% | Added |
| Renaissance Technologies LLC | 647,100 | $3.51M | 0.00% | +544,700+531.9% | Added |
| MPM Oncology Impact Management LP | 650,000 | $3.53M | 0.92% | −206,798−24.1% | Reduced |
| Marshall Wace, LLP | 994,988 | $5.40M | 0.01% | +362,810+57.4% | Added |
| Woodline Partners LP | 1,028,967 | $5.59M | 0.08% | +752,067+271.6% | Added |
| BlackRock Inc. | 1,492,509 | $8.10M | 0.00% | −27,148−1.8% | Reduced |
| Millennium Management LLC | 1,671,859 | $9.08M | 0.01% | +499,363+42.6% | Added |
| Vanguard Group Inc | 1,925,845 | $10.5M | 0.00% | +239,392+14.2% | Added |
| JPMorgan Chase & Co | 2,035,622 | $11.1M | 0.00% | −8,151−0.4% | Reduced |
| Fisher Asset Management, LLC | 2,809,444 | $15.3M | 0.01% | −125,888−4.3% | Reduced |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −884,574−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −346,000−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −223,654−100.0% | Sold out |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −137,472−100.0% | Sold out |
| EAM Global Investors LLC | 0 | $0 | 0.00% | −133,203−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −116,303−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −94,340−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −91,523−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −90,139−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −45,605−100.0% | Sold out |
| AE Wealth Management LLC | 0 | $0 | 0.00% | −44,005−100.0% | Sold out |
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −42,477−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −34,923−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −18,100−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −14,133−100.0% | Sold out |
| Beacon Pointe Advisors, LLC | 0 | $0 | 0.00% | −13,200−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −12,590−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −11,042−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −2,736−100.0% | Sold out |
| Rocky Mountain Advisers, LLC | 0 | $0 | 0.00% | −1,750−100.0% | Sold out |
| Macroview Investment Management LLC | 0 | $0 | 0.00% | −819−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −502−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Quent Capital, LLC | 0 | $0 | 0.00% | −86−100.0% | Sold out |